Illumina, Inc. (ILMN) Stock Analysis
Range Bound setup
Healthcare · Diagnostics & Research
Wait for pullback to $107.76. Weak momentum — blocks BUY_NOW at $125.84. Engine's entry $107.76 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Analyst target reached - limited upside remaining.
Illumina is a global leader in sequencing- and array-based solutions for genetic and genomic analysis, serving research institutions, hospitals, pharmaceutical companies, and diagnostic labs worldwide. Revenue comes from instrument placements, recurring consumables, and service... Read more
Wait for pullback to $107.76. Weak momentum — blocks BUY_NOW at $125.84. Engine's entry $107.76 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Analyst target reached - limited upside remaining. Chart setup: RSI 56 mid-range, Bollinger mid-band. Earnings in 0 days. Wait until post-earnings. Score 5.5/10, moderate confidence.
Passes 3/6 gates (clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicGreater China10-K Item 1A: 'Our revenue from the Greater China region, which includes China, Taiwan, and Hong Kong, was $243 million in 2025.'
- MEDIUMCustomersmall number of large, centralized laboratory customers10-K Item 1A: 'A portion of our revenue is increasingly derived from a small number of large, centralized laboratory customers.'
Material Events(8-K, last 90d)
- 2026-04-02Item 5.02LOWDirectors Frances Arnold, Robert S. Epstein, and Gary S. Guthart each notified Illumina Board of intention to retire effective May 21, 2026 (2026 annual meeting). Retirements not the result of any dispute or disagreement. David King nominated as replacement director.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $107.76. Weak momentum — blocks BUY_NOW at $125.84. Engine's entry $107.76 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Analyst target reached - limited upside remaining. Chart setup: RSI 56 mid-range, Bollinger mid-band. Earnings in 0 days. Wait until post-earnings. Target $135.02 (+7.3%), stop $97.59 (−28.9%), Setup A.R:R 2.3:1. Score 5.5/10, moderate confidence.
Take-profit target: $135.02 (+11.7% upside). Target $135.02 (+7.3%), stop $97.59 (−28.9%), Setup A.R:R 2.3:1. Stop-loss: $97.59.
Analyst target reached - limited upside remaining.
Illumina, Inc. trades at a P/E of 22.1 (forward 20.7). TrendMatrix value score: 4.9/10. Verdict: Buy (Wait for Entry).
28 analysts cover ILMN with a consensus score of 3.7/5. Average price target: $137.
What does Illumina, Inc. do?Illumina is a global leader in sequencing- and array-based solutions for genetic and genomic analysis, serving research...
Illumina is a global leader in sequencing- and array-based solutions for genetic and genomic analysis, serving research institutions, hospitals, pharmaceutical companies, and diagnostic labs worldwide. Revenue comes from instrument placements, recurring consumables, and service contracts; the Greater China region generated $243 million in 2025.